RTP Mobile Logo
The New Biology of Prostate Cancer: Exploring Basic Science to Glimpse the Future of Oncology Practice
Released May 2013

Proceedings from a CME symposium held at the 2013 Genitourinary Cancers Symposium. Featuring perspectives from Drs Kenneth J Pienta, Eleni Efstathiou, William K Oh, Nima Sharifi and Andrew J Armstrong. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE

    This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare providers involved in the research and treatment of prostate cancer (PC).

    OVERVIEW OF ACTIVITY

    Cancer of the genitourinary system affects hundreds of thousands of individuals within the United States each year and accounts for almost 30% of all newly diagnosed tumors in humans. Tumors of the prostate are among the most prevalent and thus a topic of extensive ongoing clinical research. Consequently, the management of PC is continuously in a state of evolution, necessitating rapid and consistent access to learning opportunities for medical oncologists, radiation oncologists, urologists and other healthcare providers who treat the disease. These proceedings from an interactive CME symposium held during the 2013 Genitourinary Cancers Symposium offer medical professionals a multifaceted educational experience focused specifically on the current treatment of PC.

    LEARNING OBJECTIVES

    • Determine the clinical utility of genomic studies in identifying patients with PC who might benefit from novel targeted agents.
    • Develop an understanding of the molecular states of androgen receptor activation and alterations after endocrine intervention to facilitate the rational selection and sequencing of new agents designed to suppress androgen signaling in PC.
    • Formulate an understanding of the mechanism(s) of action of antitubulins and their differential antitumor effects, induction of side effects and ability to overcome inherent and acquired resistance to other cytotoxic agents.
    • Analyze the effects of stromal-epithelial cross talk on cancer progression and the implications for therapeutic targets.
    • Assess investigational tissue- and blood-based biomarkers designed to predict the potential selective benefit of various systemic therapies in castration-resistant disease.

    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT


    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY

    This CME activity consists of a video component. The participant should watch the video.


    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Kenneth J Pienta, MD
    Professor of Medicine and Urology
    American Cancer Society Clinical Research Professor
    Director of Precision Medicine, Michigan Center for Translational Pathology
    Associate Vice President for Research, Health Sciences
    University of Michigan
    Ann Arbor, Michigan

    No real or apparent conflicts of interest to disclose.

    Eleni Efstathiou, MD, PhD
    Associate Professor
    University of Texas MD Anderson Cancer Center
    Department of Genitourinary Medical Oncology
    Houston, Texas
    Assistant Professor
    University of Athens Greece Medical School
    Department of Clinical Therapeutics
    Athens, Greece

    Advisory Committee: Bayer HealthCare Pharmaceuticals, Janssen Pharmaceuticals Inc, Millennium: The Takeda Oncology Company, Sanofi; Contracted Research: Bristol-Myers Squibb Company, Celgene Corporation, Janssen Pharmaceuticals Inc, Millennium: The Takeda Oncology Company, Sanofi.

    William K Oh, MD
    Chief, Division of Hematology and Medical Oncology
    Professor of Medicine and Urology
    Ezra M Greenspan, MD Professor in Clinical Cancer Therapeutics
    Mount Sinai School of Medicine
    Associate Director of Clinical Research
    The Tisch Cancer Institute
    New York, New York

    Consulting Agreements: Amgen Inc, Astellas, Bayer HealthCare Pharmaceuticals, Bellicum Pharmaceuticals Inc, Dendreon Corporation, Janssen Pharmaceuticals Inc, Medivation Inc, Pfizer Inc, Sanofi; Paid Research: Millennium: The Takeda Oncology Company.

    Nima Sharifi, MD
    Assistant Professor of Medicine
    Division of Hematology/Oncology
    University of Texas Southwestern Medical Center
    Dallas, Texas

    Advisory Committee: Janssen Pharmaceuticals Inc, Medivation Inc.

    Andrew J Armstrong, MD, ScM
    Associate Professor of Medicine and Surgery
    Duke Cancer Institute
    Divisions of Medical Oncology and Urology
    Duke University
    Durham, North Carolina

    Advisory Committee: Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company; Consulting Agreements: Active Biotech AB, AstraZeneca Pharmaceuticals LP, Dendreon Corporation, Sanofi; Contracted Research: Bristol-Myers Squibb Company, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi; Paid Research: Active Biotech AB, Astellas, Dendreon Corporation, Janssen Pharmaceuticals Inc, Medivation Inc, Zhejiang Kanglaite Pharmaceutical Co Ltd; Speakers Bureau: Amgen Inc, Dendreon Corporation, Pfizer Inc, Sanofi.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly USA LLC, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from Sanofi.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: May 2013
    Expiration date: May 2014

Acknowledge and close

Watch video
(WIFI is recommended for best performance):

Introduction Dr Love
Module 1: Dr Pienta Genomics of Prostate Cancer
Module 2: Dr Efstathiou Autocrine/Paracrine Drivers of Growth
Module 3: Dr Oh Tubulins and Antitubulins
Module 4: Dr Sharifi Endocrinology of Prostate Cancer
Module 5: Dr Armstrong Biomarkers in CRPC